In patients with pancreatic, ovarian, prostate, and breast cancers harboring PALB2 mutations, the clinical benefit of receiving PARPis is observed in various studies, especially in those using approaches similar to the one typically seen for BRCA-altered tumors. Here, PALB2 is linked to breast carcinoma.